- Home
- HBIO vs ALLR Comparison
HBIO vs ALLR Comparison
Compare HBIO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- ALLR
- Stock Information
- Founded
- HBIO 1901
- ALLR 2004
- Country
- HBIO United States
- ALLR United States
- Employees
- HBIO N/A
- ALLR N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- ALLR Health Care
- Exchange
- HBIO Nasdaq
- ALLR Nasdaq
- Market Cap
- HBIO 24.6M
- ALLR 20.2M
- IPO Year
- HBIO 2000
- ALLR N/A
- Fundamental
- Price
- HBIO $0.52
- ALLR $1.13
- Analyst Decision
- HBIO Buy
- ALLR Strong Buy
- Analyst Count
- HBIO 3
- ALLR 1
- Target Price
- HBIO $2.50
- ALLR $9.25
- AVG Volume (30 Days)
- HBIO 18.1M
- ALLR 284.8K
- Earning Date
- HBIO 11-06-2025
- ALLR 11-14-2025
- Dividend Yield
- HBIO N/A
- ALLR N/A
- EPS Growth
- HBIO N/A
- ALLR N/A
- EPS
- HBIO N/A
- ALLR N/A
- Revenue
- HBIO $88,750,000.00
- ALLR N/A
- Revenue This Year
- HBIO N/A
- ALLR N/A
- Revenue Next Year
- HBIO $7.02
- ALLR N/A
- P/E Ratio
- HBIO N/A
- ALLR N/A
- Revenue Growth
- HBIO N/A
- ALLR N/A
- 52 Week Low
- HBIO $0.28
- ALLR $0.61
- 52 Week High
- HBIO $2.82
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- HBIO 54.22
- ALLR 31.88
- Support Level
- HBIO $0.48
- ALLR $1.34
- Resistance Level
- HBIO $0.65
- ALLR $1.45
- Average True Range (ATR)
- HBIO 0.08
- ALLR 0.09
- MACD
- HBIO 0.02
- ALLR -0.03
- Stochastic Oscillator
- HBIO 24.55
- ALLR 8.05
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.